StockData
GENELUX Corp logo

GENELUX Corp (GNLX) stock

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.24+0.24 (+12.00%)

Close on Nov 18, 2026Market cap $101.35MP/E –Yield –

Genelux revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Genelux's revenue for the twelve months ending Dec 31, 2024 was $8.00K, down 95.3% year over year. For fiscal 2025 it was $8.00K, up 0.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.00K0.0%
FY2024Dec 31, 2024$8.00K-95.3%
FY2023Dec 31, 2023$170.00K-98.5%
FY2022Dec 31, 2022$11.07M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$8.00K-95.3%
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$170.00K–
Q4 FY2022Dec 31, 2022$68.00K–
Q3 FY2022Sep 30, 2022$11.00M–

More Genelux figures

See a number that looks wrong?